Hyperglykæmi hos personer med diabetes og kronisk nyresygdom

Julie Maria Bøggild Brøsen; Tobias Bomholt; Rikke Borg; Frederik Persson; Ulrik Pedersen-Bjergaard

doi:10.61409/V01240051

Hyperglykæmi hos personer med diabetes og kronisk nyresygdom

Translated title of the contribution: Hyperglycaemia in people with diabetes and chronic kidney disease

Julie Maria Bøggild Brøsen^*, Tobias Bomholt, Rikke Borg, Frederik Persson, Ulrik Pedersen-Bjergaard

^*Corresponding author for this work

1 Citation (Scopus)

Abstract

Assessment and treatment of hyperglycaemia in people with diabetes and chronic kidney disease (CKD) are challenging. In advanced CKD HbA1c can be unreliable, and treatment adjustments should be supported by other glucose measurements (e.g., continuous glucose monitoring (CGM) or blood glucose measurements). Glucose-lowering treatments should be evaluated based on CKD and an individualised assessment of risk factors especially hypoglycaemia. This review aims at providing an overview of the options for glycaemic monitoring and glucose-lowering treatments in people with diabetes and CKD.

Translated title of the contribution	Hyperglycaemia in people with diabetes and chronic kidney disease
Original language	Danish
Article number	V01240051
Journal	Ugeskrift for Laeger
Volume	186
Issue number	20
ISSN	0041-5782
DOIs	https://doi.org/10.61409/V01240051
Publication status	Published - 13 May 2024

Access to Document

10.61409/V01240051

Cite this

@article{43549c8aaaf84166a1cba18212b172dc,

title = "Hyperglyk{\ae}mi hos personer med diabetes og kronisk nyresygdom",

abstract = "Assessment and treatment of hyperglycaemia in people with diabetes and chronic kidney disease (CKD) are challenging. In advanced CKD HbA1c can be unreliable, and treatment adjustments should be supported by other glucose measurements (e.g., continuous glucose monitoring (CGM) or blood glucose measurements). Glucose-lowering treatments should be evaluated based on CKD and an individualised assessment of risk factors especially hypoglycaemia. This review aims at providing an overview of the options for glycaemic monitoring and glucose-lowering treatments in people with diabetes and CKD.",

keywords = "Humans, Renal Insufficiency, Chronic/complications, Hyperglycemia/complications, Hypoglycemic Agents/therapeutic use, Blood Glucose/metabolism, Blood Glucose Self-Monitoring, Glycated Hemoglobin/analysis, Diabetes Mellitus, Type 2/complications, Diabetes Mellitus/blood, Diabetic Nephropathies/complications, Risk Factors",

author = "Br{\o}sen, {Julie Maria B{\o}ggild} and Tobias Bomholt and Rikke Borg and Frederik Persson and Ulrik Pedersen-Bjergaard",

note = "Published under Open Access CC-BY-NC-BD 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/.",

year = "2024",

month = may,

day = "13",

doi = "10.61409/V01240051",

language = "Dansk",

volume = "186",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "20",

}

TY - JOUR

T1 - Hyperglykæmi hos personer med diabetes og kronisk nyresygdom

AU - Brøsen, Julie Maria Bøggild

AU - Bomholt, Tobias

AU - Borg, Rikke

AU - Persson, Frederik

AU - Pedersen-Bjergaard, Ulrik

N1 - Published under Open Access CC-BY-NC-BD 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/.

PY - 2024/5/13

Y1 - 2024/5/13

N2 - Assessment and treatment of hyperglycaemia in people with diabetes and chronic kidney disease (CKD) are challenging. In advanced CKD HbA1c can be unreliable, and treatment adjustments should be supported by other glucose measurements (e.g., continuous glucose monitoring (CGM) or blood glucose measurements). Glucose-lowering treatments should be evaluated based on CKD and an individualised assessment of risk factors especially hypoglycaemia. This review aims at providing an overview of the options for glycaemic monitoring and glucose-lowering treatments in people with diabetes and CKD.

AB - Assessment and treatment of hyperglycaemia in people with diabetes and chronic kidney disease (CKD) are challenging. In advanced CKD HbA1c can be unreliable, and treatment adjustments should be supported by other glucose measurements (e.g., continuous glucose monitoring (CGM) or blood glucose measurements). Glucose-lowering treatments should be evaluated based on CKD and an individualised assessment of risk factors especially hypoglycaemia. This review aims at providing an overview of the options for glycaemic monitoring and glucose-lowering treatments in people with diabetes and CKD.

KW - Humans

KW - Renal Insufficiency, Chronic/complications

KW - Hyperglycemia/complications

KW - Hypoglycemic Agents/therapeutic use

KW - Blood Glucose/metabolism

KW - Blood Glucose Self-Monitoring

KW - Glycated Hemoglobin/analysis

KW - Diabetes Mellitus, Type 2/complications

KW - Diabetes Mellitus/blood

KW - Diabetic Nephropathies/complications

KW - Risk Factors

UR - http://www.scopus.com/inward/record.url?scp=85194817069&partnerID=8YFLogxK

U2 - 10.61409/V01240051

DO - 10.61409/V01240051

M3 - Tidsskriftartikel

C2 - 38808757

SN - 0041-5782

VL - 186

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 20

M1 - V01240051

ER -

Hyperglykæmi hos personer med diabetes og kronisk nyresygdom

Abstract

Access to Document

Other files and links

Fingerprint

Cite this